Genetic variant of the histamine-1 receptor (glu349asp) and body weight change during clozapine treatment

Psychiatr Genet. 2002 Sep;12(3):169-71. doi: 10.1097/00041444-200209000-00009.

Abstract

Clozapine treatment frequently causes body weight gain that may impair health and may affect patient compliance. While the histamine-1 (H1) receptor may play a major role in the mechanism of the clozapine-induced body weight change, we tested the relationship between the genetic variant (Glu349Asp) of the H1 receptor and the clozapine-induced body weight change. Eighty-eight schizophrenic patients treated with clozapine were included in this study. Analysis of body weight change after 4 months of clozapine treatment showed no relationship with the H1 genotype. Further exploration of the other H1 genotypes and the antipsychotic-induced body weight change may help in the understanding of the mechanisms of antipsychotic-induced body weight gain and in the choice of patient's antipsychotic regimens.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Amino Acid Substitution
  • Body Weight / drug effects*
  • Clozapine / therapeutic use*
  • DNA Primers
  • Female
  • Genetic Variation*
  • Humans
  • Male
  • Middle Aged
  • Polymerase Chain Reaction / methods
  • Polymorphism, Genetic
  • Receptors, Histamine H1 / genetics*
  • Schizophrenia / drug therapy*
  • Serotonin Antagonists / therapeutic use*

Substances

  • DNA Primers
  • Receptors, Histamine H1
  • Serotonin Antagonists
  • Clozapine